Cingulate Inc. (NASDAQ: CING) announced that the United States Patent and Trademark Office issued the company its first wholly owned U.S. patent covering its lead drug candidate, CTx-1301 (dexmethylphenidate HCl), an ADHD treatment in development.

The patent, U.S. Patent No. 12,653,791, was issued June 16, 2026, and provides protection through December 2042. Titled "Trimodal, Precision-Timed Pulsatile Release Tablet," it covers composition-of-matter, formulation, structural, and method-of-treatment claims related to CTx-1301's tablet technology, which is designed to release medication in three distinct phases from a single daily dose.

Cingulate CEO Shane J. Schaffer said in a statement: "This patent represents another important milestone in protecting the technology that differentiates CTx-1301 and underpins our proprietary Precision Timed Release™ Platform."

In addition to the U.S. patent, Cingulate holds patents in 30 European territories, including the United Kingdom, as well as in Australia, Canada, and Israel. Patent applications are pending in Hong Kong and the Republic of Korea.

CTx-1301 is being evaluated for ADHD treatment under the FDA's 505(b)(2) regulatory pathway. Cingulate is also developing CTx-1302 as a once-daily ADHD treatment and CTx-2103, a once-daily tablet targeting anxiety disorders.